Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study

• DOI: 10.2147/jhc.s352480
• Publication Date: 2022-03-07T14:20:25Z
• Authors: Kongying Lin; Fuqun Wei; Qizhen Huang; Zisen Lai; Jinyu Zhang; Qingjing Chen; Yabin Jiang; Jie Kong; Shichuan Tang; Jianhuai Lin; Yufeng Chen; Jinhong Chen; Yongyi Zeng
• Keywords: tace; 03 medical and health sciences; 0302 clinical medicine; early-recurrence; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; hepatocellular carcinoma; resection; tki; Journal of Hepatocellular Carcinoma; RC254-282; Original Research; 3. Good health

Purpose: This study aimed to assess the efficacy and safety of adjuvant transarterial chemoembolization (TACE) plus tyrosine kinase inhibitor (TKI) treatment in patients with hepatocellular carcinoma (HCC) a high risk early recurrence after curative resection. Patients Methods: from multiple centres were divided into postoperative TACE (n=57) or without (n=142) TKI administration groups. The disease-free survival (DFS) curve was depicted by Kaplan–Meier method, difference between two groups tested using log rank test. Univariate multivariate Cox analyses performed identify independent factors for DFS. Additionally, three propensity score minimise potential confounding facilitate more reliable conclusion. Adverse events (AEs) assessed according Common Terminology Criteria Events, version 4.0. Results: 1-and 2-year DFS rates group 45.5% 34.9%, respectively, which significantly better than those alone (26.8% 18.3%, respectively). Multivariate analysis identified as an prognostic factor (hazard ratio: 0.611, 95% confidence interval: 0.408– 0.915, P=0.017). Further based on various methods yielded similar results. Subgroup showed that tumour diameter ≥ 5 cm, number < 3, absence hepatic vein thrombus bile duct thrombus, ruptured tumours, stage IIIB could benefit (all P< 0.05). Some (33.33%) experienced grade 3 AEs group. Conclusion: can reduce incidence tolerable adverse HCC at hepatectomy may be appropriate option anti-recurrence treatment. Keywords: carcinoma, resection, TACE, TKI, early-recurrence